Nobiletin inhibits non-small cell lung cancer through TRKC and exhibits a synergistic effect with the HDAC inhibitor

Abstract

Approximately 85% of all lung cancer cases are classified as non-small cell lung cancer (NSCLC). Given its poor prognosis and resistance to radiotherapy and chemotherapy, there is an urgent need to elucidate its molecular mechanisms to develop novel and more effective therapeutic strategies. In prior research, we identified nobiletin from a compound library and confirmed it as a novel natural BH3 mimetic. Nobiletin synergized with vorinostat to induce autophagy and apoptosis in small-cell lung cancer. In the current study, we further demonstrate that nobiletin, either alone or in combination with vorinostat, exerts inhibitory effects on NSCLC. Specifically, the combination of nobiletin and vorinostat suppressed the proliferation of NSCLC A549 cells. Nobiletin, used alone or with vorinostat, induced apoptosis in A549 cells by mimicking BH3-only proteins, which included down-regulating anti-apoptotic proteins such as B-cell lymphoma-2 (BCL-2) and MCL-1, up-regulating apoptosis-related proteins Cleaved-Caspase-3 and Cleaved-PARP, and increasing BH3-only protein expression. Nobiletin binding to BCL-2 facilitated the dissociation of the Beclin-1/BCL-2 complex, thereby elevating levels of free Beclin-1. Furthermore, the combination of nobiletin and vorinostat enhanced the expression of LC3A/BII and forkhead box O1 (FOXO1), ultimately inducing autophagy in A549 cells. Eukaryotic transcriptome sequencing revealed that the combination treatment primarily inhibits tumor cell proliferation by modulating TRKC protein expression and suppressing phosphorylation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway. Therefore, our results indicate that nobiletin, a natural BH3 mimetic, synergizes with vorinostat to regulate both apoptosis and autophagy in NSCLC.

Keywords

Nobiletin / Vorinostat / Non-small cell lung cancer / NTRK3 / BH3-only proteins

Funding

This project was supported by the National Natural Science Foundation of China (Nos. 82073878, 81874318, 81673453, and 82473947).

Declaration of competing interest

The authors declare no conflicts of interest.

References

[1] Liu YF, Cheng WX, Xin HY, et al. Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy. Cancer Nanotechnol. 2023; 14(1):28. https://doi.org/10.1186/s12645-023-00174-x.

[2] Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017; 389(10066):299-311. https://doi.org/10.1016/S0140-6736(16)30958-8.

[3] Mukhopadhyay S, Panda PK, Sinha N, et al. Autophagy and apoptosis: where do they meet.? Apoptosis. 2014; 19(4):555-566. https://doi.org/10.1007/s10495-014-0967-2.

[4] Li YQ, Fan F, Wang YR, et al. The novel small molecule BH3 mimetic nobiletin synergizes with vorinostat to induce apoptosis and autophagy in small cell lung cancer. Biochem Pharmacol. 2023; 216:115807. https://doi.org/10.1016/j.bcp.2023.115807.

[5] Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2009; 66(8):1326-1336. https://doi.org/10.1007/s00018-008-8637-6.

[6] Mallick S, Patil R, Gyanchandani R, et al. Human oral cancers have altered expression of Bcl-2 family members and increased expression of the anti-apoptotic splice variant of Mcl-1. J Pathol. 2009; 217(3):398-407. https://doi.org/10.1002/path.2459.

[7] Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019; 20(3):175-193. https://doi.org/10.1038/s41580-018-0089-8.

[8] Shahar N, Larisch S. Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resist Updat. 2020; 52:100712. https://doi.org/10.1016/j.drup.2020.100712.

[9] Uthale A, Anantram A, Sulkshane P, et al. Identification of bicyclic compounds that act as dual inhibitors of Bcl-2 and Mcl-1. Mol Divers. 2023; 27(3):1359-1374. https://doi.org/10.1007/s11030-022-10494-6.

[10] Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 2018; 25(1):46-55. https://doi.org/10.1038/cdd.2017.179.

[11] Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014; 15(1):49-63. https://doi.org/10.1038/nrm3722.

[12] Shukla S, Saxena S, Singh BK, et al. BH3-only protein BIM: an emerging target in chemotherapy. Eur J Cell Biol. 2017; 96(8):728-738. https://doi.org/10.1016/j.ejcb.2017.09.002.

[13] Ashkenazi A, Fairbrother WJ, Leverson JD, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017; 16(4):273-284. https://doi.org/10.1038/nrd.2016.253.

[14] Wang Y, Fan S, Li X, et al. The novel small molecular BH3 mimetics SM3 and its regulation of cell apoptosis and autophagy. Biochem Biophys Res Commun. 2019; 517(1):15-22. https://doi.org/10.1016/j.bbrc.2019.06.068.

[15] Cajas YN, Cañón-Beltrán K, Ladrón de Guevara M, et al. Antioxidant nobiletin enhances oocyte maturation and subsequent embryo development and quality. Int J Mol Sci. 2020; 21(15):5340. https://doi.org/10.3390/ijms21155340.

[16] Deveci Ozkan A, Kaleli S, Onen HI, et al. Anti-inflammatory effects of nobiletin on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer cells. Immunopharmacol Immunotoxicol. 2020; 42(2):93-100. https://doi.org/10.1080/08923973.2020.1725040.

[17] Lee SH, Li XH, Lu QY, et al. Nobiletin enhances mitochondrial function by regulating SIRT1/PGC-1α signaling in porcine oocytes during in vitro maturation. Biochem Biophys Res Commun. 2024; 706:149747. https://doi.org/10.1016/j.bbrc.2024.149747.

[18] Chen M, Li H, Zheng S, et al. Nobiletin targets SREBP1/ACLY to induce autophagy-dependent cell death of gastric cancer cells through PI3K/Akt/mTOR signaling pathway. Phytomedicine. 2024; 128:155360. https://doi.org/10.1016/j.phymed.2024.155360.

[19] Liu E, Chen Y, Qin M, et al. Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia. Eur J Med Chem. 2024; 276:116663. https://doi.org/10.1016/j.ejmech.2024.116663.

[20] Nakajima W, Sharma K, Hicks MA, et al. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. Cancer Biol Ther. 2016; 17(1):27-35. https://doi.org/10.1080/15384047.2015.1108485.

[21] Heinicke U, Haydn T, Kehr S, et al. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. Oncogene. 2018; 37(39):5325-5339. https://doi.org/10.1038/s41388-018-0212-5.

[22] Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-681. https://doi.org/10.1124/pr.58.3.10.

[23] Das S, Shukla N, Singh SS, et al. Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis. 2021; 26(9-10):512-533. https://doi.org/10.1007/s10495-021-01687-9.

[24] Zeng S, Jiang K, Ge J, et al. NTRK fusion promotes tumor migration and invasion through epithelial-mesenchymal transition and closely interacts with ECM1 and NOVA1. BMC Cancer. 2024; 24(1):1502. https://doi.org/10.1186/s12885-024-13271-w.

[25] Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022; 72(5):409-436. https://doi.org/10.3322/caac.21731.

[26] Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-681. https://doi.org/10.1038/nature03579.

[27] Deeks ED.Venetoclax: First Global Approval. Drugs. 2016; 76(9):979-987. https://doi.org/10.1007/s40265-016-0596-x.

[28] González-Gualda E, Pàez-Ribes M, Lozano-Torres B, et al. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. Aging Cell. 2020; 19(4):e13142. https://doi.org/10.1111/acel.13142.

[29] Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008; 68(9):3421-3428. https://doi.org/10.1158/0008-5472.CAN-07-5836.

[30] Fowler-Shorten DJ, Hellmich C, Markham M, et al. BCL-2 inhibition in haematological malignancies: clinical application and complications. Blood Rev. 2024; 65:101195. https://doi.org/10.1016/j.blre.2024.101195.

[31] Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010; 11(12):1149-1159. https://doi.org/10.1016/S1470-2045(10)70261-8.

[32] Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017; 130(22):2401-2409. https://doi.org/10.3410/f.731966596.793537928.

[33] Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019; 133(18):1964-1976. https://doi.org/10.1182/blood-2018-11-880526.

[34] Moazamiyanfar R, Rezaei S, AliAshrafzadeh H, et al. Nobiletin in cancer therapy; mechanisms and therapy perspectives. Curr Pharm Des. 2023; 29(22):1713-1728. https://doi.org/10.2174/1381612829666230426115424.

[35] Zhang RJ, Chen J, Mao LZ, et al. Nobiletin triggers reactive oxygen species-mediated pyroptosis through regulating autophagy in ovarian cancer cells. J Agric Food Chem. 2020; 68(5):1326-1336. https://doi.org/10.1021/acs.jafc.9b07908.

[36] Lee JH, Choy ML, Marks PA. Mechanisms of resistance to histone deacetylase inhibitors. Adv Cancer Res. 2012; 116:39-86. https://doi.org/10.1016/b978-0-12-394387-3.00002-1.

[37] West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124(1):30-39. https://doi.org/10.1172/JCI69738.

[38] Whitecross KF, Alsop AE, Cluse LA, et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 2009; 113(9):1982-1991. https://doi.org/10.1182/blood-2008-05-156851.

[39] Yaqoob MD, Xu L, Li CF, et al. Targeting mitochondria for cancer photodynamic therapy. Photodiagnosis Photodyn Ther. 2022; 38:102830. https://doi.org/10.1016/j.pdpdt.2022.102830.

[40] Warren CFA, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019; 10(3):177. https://doi.org/10.1038/s41419-019-1407-6.

[41] Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007; 26(9):1324-1337. https://doi.org/10.1038/sj.onc.1210220.

[42] Jochems F, Baltira C, MacDonald JA, et al. Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state. Cell Death Differ. 2024; 32:855-865. https://doi.org/10.1038/s41418-024-01439-7.

[43] Shahbandi A, Rao SG, Anderson AY, et al.BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. Cell Death Differ. 2020; 27(11):3097-3116. https://doi.org/10.1038/s41418-020-0564-6.

[44] Amatu A, Sartore-Bianchi A and Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016; 1(2):e000023. https://doi.org/10.1136/esmoopen-2015-000023.

[45] Ivanov SV, Panaccione A, Brown B, et al. TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior. Oncogene. 2013; 32(32):3698-3710. https://doi.org/10.1038/onc.2012.377.

[46] Repetto M, Chiara Garassino M, Loong HH, et al. NTRK gene fusion testing and management in lung cancer. Cancer Treat Rev. 2024; 127:102733. https://doi.org/10.1016/j.ctrv.2024.102733.

[47] Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017; 173:58-66. https://doi.org/10.1016/j.pharmthera.2017.02.006.

[48] Huang WJ, Huang YH, Gu JY, et al. miR-23a-5p inhibits cell proliferation and invasion in pancreatic ductal adenocarcinoma by suppressing ECM1 expression. Am J Transl Res. 2019; 11(5):2983-2994.

[49] Kyker-Snowman K, Hughes RM, Yankaskas CL, et al. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Res Treat. 2020; 179(3):631-642. https://doi.org/10.1007/s10549-019-05506-3.